the aid library

LIST OPTIONS

Filter

3184

Sort by:

Direction:

Download (1389)

View PDF (3026)

Tuberculosis. Practical guide for clinicians, nurses, laboratory technicians and medical auxiliaries

Médecins sans Frontières MSF (2022) C2

This Tuberculosis guide has been developed jointly by Médecins Sans Frontières and Partners In Health. It aims at providing useful information to the clinicians and health staff for the comprehensive management of tuberculosis. Forms of susceptible and resistant tuberculosis, tuberculosis in child... more

Download (739)

View PDF (1760)

Evaluation of Ebola response - Uganda

Sigridur B.Thormar IFRC (2013)

The main aim of this assessment was to evaluate the PSS response of URCS to these VHF, against the needs of beneficiaries and communities focused on the areas of most ‘added value’ of the URCS; community engagement mobilisation and support, documenting any unintended outcomes and best practice r... more

Download (441)

View PDF (970)

WHO consolidated guidelines on drug-resistant tuberculosis treatment
recommended

World Health Organization WHO; Stop TB (2019) C_WHO

The present Consolidated guidelines include a comprehensive set of WHO recommendations for the treatment and care of DR-TB, derived from these WHO guidelines documents. The consolidated guidelines include policy recommendations on treatment regimens for isoniazid-resistant TB (Hr-TB) and MDR/RR-TB, ... more

Download (179)

View PDF (254)

2007 Rwanda Service Provision Assessment Survey Policy Brief

National Institute of Statistics of Rwanda (NISR) [Rwanda], Ministry of Health (MOH) [Rwanda], and ICF International (2008) C2

Policy brief based on the 2007 Rwanda Service Provision Assessment (RSPA) survey. The 2007 RSPA survey describes how the formal health sector in Rwanda provides services for family planning, maternal health, child health, malaria, HIV/AIDS, and other communicable diseases.

Download (414)

View PDF (402)

Global strategy to accelerate the elimination of cervical cancer as a public health problem

World Health Organization WHO (2020) C_WHO

WHO‘s Global Strategy to Accelerate the Elimination of Cervical Cancer, launched today, outlines three key steps: vaccination, screening and treatment. Successful implementation of all three could reduce more than 40% of new cases of the disease and 5 million related deaths by 2050.

Download (159)

View PDF (202)

Nurses and midwives: a vital resource for health

World Health Organization WHO, Regional Office of Europe (2022) C_WHO

This European compendium was produced to provide operational examples of the new nursing and midwifery roles and new service delivery models currently being employed across the Region. The case studies directly relate to the priority areas in Health 2020 and exemplify the types of activities needed ... more

Download (209)

View PDF (217)

Implications of the COVID-19 pandemic for patient safety: a rapid review

World Health Organization WHO (2022) C_WHO

The pandemic has emphasized the high risk of avoidable harm to patients, health workers, and the general public, and has identified a range of safety gaps across all core components of health systems at all levels. The rapid review ‘Implications of the COVID-19 pandemic for patient safety’ ex... more

Download (105)

View PDF (163)

Nigeria: Demographic Health Survey 2018

The DHS Program ICF USAID (2019) C2

The 2018 NDHS is a national sample survey that provides up-to-date information on demographic and health indicators. The sample was selected using a stratified, two-stage cluster design, with enumeration areas (EAs) as the sampling units for the first stage. The second stage was a complete listing o... more

Download (195)

View PDF (210)

WHO's Health Emergency Appeal 2023

World Health Organisation (WHO) (2023) C_WHO

WHO needs US$2.54 billion to provide life-saving assistance to millions of people around the world facing health emergencies. WHO’s Health Emergency Appeal is a consolidation of WHO’s priorities and financial requirements for 2023 to carry out health interventions in emergency and humanitarian r... more

Download (218)

View PDF (190)

Addressing violence against women in health policies and protocols in the Americas: A regional status report

World Health Organisation (WHO) (2023) C_WHO

Violence against women and girls is widespread in the Region of the Americas, resulting in enormous consequences for the health and wellbeing of women and girls, their families and communities. These costs are unacceptable and they can be prevented through evidence-based action, including the health... more

Download (121)

View PDF (142)

Intention to action series: Regional reflections. Analysis from informal regional consultations with people living with noncommunicable diseases and mental health conditions

World Health Organisation (WHO) (2023) C_WHO

This report includes analysis from informal regional consultations in the African Region, the Caribbean and North America, Latin America, South-East Asia Region, European Region, Eastern Mediterranean Region, alongside three forums in the Western Pacific Region. It analyses the overarching similarit... more

Download (100)

View PDF (384)

Donor Funding for Newborn Survival: An Analysis of Donor-Reported Data, 2002–2010

Pitt1, C.; J. E. Lawn; M. Ranganathan et al. PLoS Med (2012) CC

Background:Neonatal mortality accounts for 43% of global under-five deaths and is decreasing more slowly than maternal or child mortality. Donor funding has increased for maternal, newborn, and child health (MNCH), but no analysis to date has disaggregated aid for newborns. We evaluated if and how a... more

Download (250)

View PDF (205)

Infection prevention and control guideline for Ebola and Marburg disease, August 2023
recommended

World Health Organization WHO (2023) CC

Ebola disease and Marburg disease outbreaks continue to occur in Africa, with increased frequency. In addition to resulting in high mortality and morbidity, the outbreaks generate fear and mistrust about the response activities within the communities affected. Infection prevention and control (IP... more

Download (245)

View PDF (330)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (34)

View PDF (28)

Resource Effective Strategies to Prevent and Treat Cardiovascular Disease

Schwalm, J.; McKee, M.; Huffman, M. et al. Circulation (2016) CC

Cardiovascular disease (CVD) is the leading cause of global deaths, with the majority occurring in low- and middle-income countries (LMIC). The primary and secondary prevention of CVD is suboptimal throughout the world, but the evidence-practice gaps are much more pronounced in LMIC. Barriers at the... more

Download (24)

View PDF (23)

World Heart Federation Roadmap for Heart Failure

Ferreira, J.P.; Kraus, S.; Mitchell, S. et al. Global Heart (2019) CC

In 2012, all Member States of the World Health Organization (WHO) endorsed a historical target to reduce premature mortality from noncommunicable diseases (NCD). This commitment was echoed in 2015 by the United Nations Sustainable Development Goals, which included a target to reduce premature morta... more

Download (409)

View PDF (121)

National Guideline For Emergency Nutrition Intervention (May 2022)

Government of Ethiopia (2022) CC

Humanitarian crises exacerbate nutritional risks and often lead to an increase in acute malnutrition. Emergencies include both manmade (conflict) and natural disasters (floods, drought, cyclones, typhoons, earthquakes, volcanic eruptions, etc.). Complex emergencies are combinations of both manmade a... more

Download (17)

View PDF (15)

Intention to action series: Regional reflections. Analysis from informal regional consultations with people living with noncommunicable diseases and mental health conditions 2023 WHO

World Health Organization (WHO) World Health Organization (WHO) (2023) C_WHO

Download (18)

View PDF (14)

Communicable and non-communicable diseases in Africa in 2021/22

World Health Organization Africa Region; WHO Africa World Health Organization Africa Region; WHO Africa (2023) C_WHO

This report is one of the first major products of the newly established Precision Public Health Metrics unit of the UCN cluster of the WHO Regional Office for Africa. The report presents national trends in communicable and non-communicable disease burden and control in the WHO African region. It tra... more

Download (4)

View PDF (5)

Antimicrobial Resistance Surveillance Guidance for the African Region

Africa Center for Disease Control and Prevention (2024) CC

Antimicrobials are medicines, including antibiotics, antivirals, antifungals, and antiparasitics, that are used to prevent and treat infections in humans, animals, and plants. Antimicrobial Resistance (AMR) arises when bacteria, viruses, fungi, and parasites no longer respond to these medicines, ren... more

WHO consolidated guidelines on drug-resistant tuberculosis treatment recommended

Infection prevention and control guideline for Ebola and Marburg disease, August 2023 recommended

WHO consolidated guidelines on drug-resistant tuberculosis treatment
recommended

Infection prevention and control guideline for Ebola and Marburg disease, August 2023
recommended